Insider Selling: Twist Bioscience Co. (NASDAQ:TWST) SVP Sells 1,057 Shares of Stock

Twist Bioscience Co. (NASDAQ:TWST) SVP Paula Green sold 1,057 shares of the business’s stock in a transaction that occurred on Monday, November 4th. The stock was sold at an average price of $41.56, for a total value of $43,928.92. Following the transaction, the senior vice president now owns 121,013 shares in the company, valued at $5,029,300.28. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Paula Green also recently made the following trade(s):

• On Wednesday, October 2nd, Paula Green sold 3,310 shares of Twist Bioscience stock. The stock was sold at an average price of $43.21, for a total value of $143,025.10.
• On Friday, September 20th, Paula Green sold 297 shares of Twist Bioscience stock. The stock was sold at an average price of $46.94, for a total value of $13,941.18.

Twist Bioscience Price Performance

NASDAQ TWST traded up $2.28 during trading hours on Wednesday, hitting $45.42. The company had a trading volume of 1,019,545 shares, compared to its average volume of 942,883. Twist Bioscience Co. has a fifty-two week low of $15.85 and a fifty-two week high of $60.90. The company has a market capitalization of $2.66 billion, a price-to-earnings ratio of -11.89 and a beta of 1.78. The firm’s 50 day moving average is $43.61 and its 200 day moving average is $45.43.

Wall Street Analyst Weigh In

TWST has been the topic of a number of research reports. Leerink Partners upped their price target on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a report on Thursday, October 17th. Barclays reduced their target price on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a research note on Monday, August 5th. Evercore ISI upped their target price on Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. The Goldman Sachs Group upped their target price on Twist Bioscience from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Tuesday, July 9th. Finally, Robert W. Baird upped their target price on Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a research note on Monday, August 5th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $51.22.

Institutional Trading of Twist Bioscience

Large investors have recently added to or reduced their stakes in the stock. Signaturefd LLC increased its holdings in Twist Bioscience by 63.0% in the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after purchasing an additional 306 shares in the last quarter. EdgeRock Capital LLC acquired a new stake in Twist Bioscience in the 2nd quarter valued at $43,000. Blue Trust Inc. grew its stake in shares of Twist Bioscience by 2,912.8% during the second quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock valued at $58,000 after acquiring an additional 1,136 shares in the last quarter. DekaBank Deutsche Girozentrale acquired a new stake in shares of Twist Bioscience during the second quarter valued at about $61,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Twist Bioscience by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock valued at $98,000 after acquiring an additional 381 shares in the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.